Home » Topics » Regulatory » EMA

EMA
RSS

Ocata granted European ATMP designation for RPE program for macular degeneration

Nov. 26, 2014

ATX-F8-117 receives European orphan medicinal product designation for hemophilia A

Nov. 26, 2014

Vorapaxar receives positive opinion from EMA

Nov. 25, 2014

EMA committee recommends approval of Travatan for use in pediatric patients

Nov. 25, 2014

CHMP recommends granting marketing authorization for Shionogi's Senshio

Nov. 25, 2014

EMA issues new recommendations for the use of Corlentor/Procoralan

Nov. 25, 2014

CHMP backs Otezla for psoriasis and psoriatic arthritis

Nov. 24, 2014

CHMP adopts positive opinion for Genzyme's Cerdelga

Nov. 24, 2014

EMA gives positive opinion for hepatitis C therapy Viekirax plus Exviera

Nov. 24, 2014

Palovarotene receives EMA orphan medicinal product designation

Nov. 24, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...